Clearmind advances CMND-100 into alcohol use disorder patients after Phase I/II safety milestone

Clearmind Medicine advanced its FDA-regulated Phase I/II trial of CMND-100 into patient testing for alcohol use disorder.

Results were already presented from Part A, which met the primary safety endpoint and showed tolerability in healthy participants.

Part B will test CMND-100 in moderate to severe alcohol use disorder patients, targeting early signs of reduced drinking and craving.

Part C will dose healthy participants for five days to further characterize the safety and tolerability profile.